Medical network - April 1 as the roll in during the annual report of listed companies, in the first quarter of 2017 earnings forecast is emerging. According to statistics, as of March 31, a total of 50 drug companies to disclose the first-quarter earnings forecast. Among them, the letter litai net profit is expected to exceed 400 million yuan, rui kang pharmaceutical, mastery in pharmaceutical industry, wing on pharmaceutical or double seven's net profit growth. 

 

Table 1:1 - March 17 years medicine enterprise performance forecast (unit: ten thousand yuan) 

 

 

Note: as of March 31 

 

Data sources: Oriental wealth 

 

1, the letter litai net profit is expected to exceed 400 million yuan 

 

Table 1 - March 17 years I completely believe litai performance is expected 

 

 

Litai is believed, according to the annual report in March 1, 2017 net profit attributable to shareholders of listed companies is expected to reach 357.835 million ~ 411.5103 million yuan, increase in 0% ~ 15%, earnings growth is mainly we will further improve the company's marketing network, sales promotion efforts, agents product sales continue to maintain steady growth, increased profit contribution. 

 

In 2016, xinli Thai business revenue 383349.02 of ten thousand yuan, up 10.23% from a year earlier. Net profit attributable to shareholders of listed companies 139641 staged a ten thousand yuan, up 10.31% from a year earlier, to achieve revenue and profit growth. Company around high-end chemical medicine, biological medicine, biological medical three innovation, focus on the field of cardiovascular, fall blood sugar, antitumor, orthopaedic field, deepening research platform construction, continue to enrich product line, with innovation advantages to establish the leading position in the field of cardiovascular. 

 

In the field of cardiovascular medicine, xinli Thai products has formed "pyramid" shape echelon type structure, the main products tai jia continues to maintain competitive advantage, and rapid growth; With independent intellectual property rights of national class 1.1 innovation medicine -- xinli temple carried out academic promotion, phase iv clinical accelerating, provide strong support for the market access; Tegus ning has entered a stage of rapid volume; Innovation of biological medicine, biology, medical research and development and steadily move, further enrich the company product line, improve the comprehensive competitiveness. 

 

2, 4 drug firms net income or an increase of 200% 

 

According to the statistics show that in the first quarter of 2017 net profit of the double seven drug firms, among them, rui kang pharmaceutical, mastery in pharmaceutical industry, purple xin pharmaceutical, wing on pharmaceutical industry is expected to grow 200%. 

 

Rui kang pharmaceutical 

 

Net profit: 26065.36 ~ 303.3837 million yuan 

 

Rose: 205.00% ~ 255.00% 

 

First-quarter earnings growth main reasons: one is that business has grown steadily in the province; Second, fujian association of foreign languages and rapid expansion of business; Three is accounts receivable bad debts provision ratio changes. In 2016, the company in business steady growth in the province, fujian association of foreign languages and rapid acquisition, the annual total income of 1561866.62 achieved ten thousand yuan, up 60.19% from a year earlier, to achieve net profit attributable to the parent company owners 59075 total of ten thousand yuan, up 150.39% from a year earlier. 

 

Purple xin pharmaceutical co. 

 

Net profit: 3000 ~ 34 million yuan 

 

Rose: 182.36% ~ 220.01% 

 

First-quarter earnings growth is mainly purple xin pharmaceutical main business revenue growth. , according to 2016 results letters purple xin pharmaceutical revenue 81955 total of ten thousand yuan, up 29.42% from a year earlier. Earnings growth is primarily a proprietary Chinese medicine products as the OTC products market gradually, sales revenue increases; Ginseng products deep processing of products leads to increased sales. 

 

Mastery in pharmaceutical co. 

 

Net profit: 8400 ~ 92 million yuan 

 

Rose: 175.02% ~ 201.22% 

 

First-quarter earnings growth, on the one hand, from with the perfect industrial chain and group, the overall scale advantages, enhance core competitiveness, continue to promote the market development, achieve sustained growth in revenue and gross margin; On the other hand rose to merge range, yantai only chu pharmaceutical and table in June 2016, in the first quarter of last year without. 

 

Yongan pharmaceutical co. 

 

Net profit: 2264.85 ~ 27.1782 million yuan 

 

Rose: 150% ~ 200% 

 

Learned, yongan pharmaceutical target is to the health industry transformation, cultivate new growth point. In February 2017, the company set up a wholly owned subsidiary in Canadian investment in aino d co., LTD. (Inoyan Laboratories Inc), used for operating dietary supplements Innovite brand. In march, the company set up in aino investment d healthy technology co., LTD. (wuhan), obtained the business license issued by the wuhan city administration for industry and commerce. Scope of business for medicine, health food, pre-packaged food, food additives, chemical products (excluding dangerous goods) of research and development, technology consulting, wholesale and retail; Goods import and export, technology import and export, import and export agent (excluding countries ban or restrict the import and export of goods and technologies). 

 

In first-quarter earnings forecast disclosure of listed companies, a total of 28 beforehand. However their final performance? Looking forward to "report card" in the first quarter, giving the answer.